DPP4 and type 2 diabetes mellitus: Liraglutide and semaglutide are the long-acting GLP-1 analogs, which are immune to cleavage by dipeptidyl peptidase-4 (DPP-4), thereby producing extended in vivo action, resulting in beneficial effects in T2DM patients.